<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978107</url>
  </required_header>
  <id_info>
    <org_study_id>TG4023.01</org_study_id>
    <secondary_id>Eudra CT 2008-005024-90</secondary_id>
    <nct_id>NCT00978107</nct_id>
  </id_info>
  <brief_title>Trial of TG4023 Combined With Flucytosine in Liver Tumors</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous&#xD;
      intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of&#xD;
      5-fluorocytosine in patients with primary or secondary hepatic tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response of injected and non-injected lesions Viral dissemination Proof of concept: 5-FU concentration in plasma and in tumors</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-FCU1, flucytosine</intervention_name>
    <description>TG4023: single IT injection; possibility to re-administer once,&#xD;
Percutaneous IT injections, under radiological or ultrasound imaging guidance&#xD;
Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),&#xD;
MTD injected to up to 3 different lesions (Cohort #4)&#xD;
5-FC (5-fluorocytosine)/flucytosine&#xD;
Dose and dosing schedule:&#xD;
Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L&#xD;
Duration: 2 weeks.&#xD;
Possible routes of administration:&#xD;
PO: 500 mg tablets, qid&#xD;
IV: 1% 250 mL vials, 45-minute infusions.</description>
    <other_name>5-FC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced disease without any other standard of care treatment options:&#xD;
&#xD;
               -  hepatic metastases of colorectal cancer (CRC) or of other cancers&#xD;
&#xD;
               -  Hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  At least one unresectable target tumor located in the liver, measuring 2-5 cm and&#xD;
             accessible to IT administration of TG4023 and amenable to radiological measurement&#xD;
             using RECIST,&#xD;
&#xD;
          -  Weight ≤ 100 kg,&#xD;
&#xD;
          -  Patients with stable disease, who have to discontinue chemotherapy because of&#xD;
             intolerance,&#xD;
&#xD;
          -  ECOG performance status ≤ 2,&#xD;
&#xD;
          -  Life expectancy ≥ 3 months,&#xD;
&#xD;
          -  Hematology:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,500/mm3,&#xD;
&#xD;
               -  Hemoglobin &gt; 9g/dL,&#xD;
&#xD;
               -  Platelet count &gt; 100,000/mm3,&#xD;
&#xD;
               -  Prothrombin time international normalized ratio (INR) ≤ 2; partial thromboplastin&#xD;
                  time ≤ 1.66 times upper limit of normal (ULN),&#xD;
&#xD;
          -  Biochemistry:&#xD;
&#xD;
               -  Total bilirubin ≤ 3 x ULN,&#xD;
&#xD;
               -  Aspartate amino-transferase (AST), alanine amino-transferase (ALT), alkaline&#xD;
                  phosphatase&#xD;
&#xD;
                    -  5.0 x ULN,&#xD;
&#xD;
               -  Creatinin clearance ≥ 40 mL/min,&#xD;
&#xD;
               -  Total albumin ≥ 30 g/L,&#xD;
&#xD;
          -  Anti-vitamin K anticoagulants should have been switched for low-molecular weight&#xD;
             heparin prior to TG4023 injection,&#xD;
&#xD;
          -  Signed, written Independent Ethics Committee (IEC)-approved informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh stage C hepatic insufficiency,&#xD;
&#xD;
          -  Impaired renal function (creatinin clearance &lt; 40 mL/min),&#xD;
&#xD;
          -  Known deficiency in dihydropyrimidine dehydrogenase (DPD) or total DPD deficiency&#xD;
             diagnosed at baseline in those patients not previously treated with 5-FU-related&#xD;
             compounds,&#xD;
&#xD;
          -  Ascites,&#xD;
&#xD;
          -  Brain metastases,&#xD;
&#xD;
          -  Significant impairment of gastro-intestinal (GI) tract absorption capacity, such as&#xD;
             total gastrectomy, gastric mucosal atrophy, extensive intestinal resections or&#xD;
             malabsorption disease will not be treated by oral 5-FC,&#xD;
&#xD;
          -  History of bleeding disorders,&#xD;
&#xD;
          -  Pregnant or breast-feeding women,&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV) positive,&#xD;
&#xD;
          -  Chronic use of immunodepressants within 4 weeks prior to TG4023 injection or&#xD;
             immune-depressed patients,&#xD;
&#xD;
          -  Hypersensitivity to 5-FC,&#xD;
&#xD;
          -  Hypersensitivity to egg proteins,&#xD;
&#xD;
          -  Concomitant or previous chemotherapy or targeted therapy within 4 weeks prior to&#xD;
             TG4023 injection and last treatment with bevacizumab (Avastin®) within 2 months prior&#xD;
             to TG4023 injection,&#xD;
&#xD;
          -  Concomitant treatment with anti-inflammatory drugs: systemic cortico-steroids and&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs),&#xD;
&#xD;
          -  Prior gene therapy,&#xD;
&#xD;
          -  Prior participation in any other research protocol involving an IMP within 2 months&#xD;
             prior to TG4023 injection,&#xD;
&#xD;
          -  Major surgery within 6 weeks of TG4023 injection,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette,</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Lyon,</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M, Balloul JM. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther. 2008 Jan;15(1):18-28. Epub 2007 Nov 9.</citation>
    <PMID>17992203</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic tumors</keyword>
  <keyword>Metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flucytosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

